US-only at start
Core English
For pre-CE / pre-MDR companies focused on US clinical studies and FDA milestones with no near-term EU commercialization.
€2,250 net
Choose Core English
Industry · Healthcare
Wikipedia for healthcare & digital health companies
For med-device manufacturers, digital therapeutics, telehealth platforms and clinical-stage biotech, Wikipedia presence is checked by clinicians, hospital procurement, regulators and payers as part of standard due diligence. The bar is higher — and so is the value of clearing it cleanly.
Why it matters in healthcare
Where healthcare Wikipedia presence is checked
Healthcare buying involves more stakeholders than any other tech sector — clinicians, IT, security, compliance, formulary, finance. Each one runs public-source checks separately.
Clinician research
Physicians and nurses look up unfamiliar med-devices and digital tools mid-shift. Wikipedia is one of the first places they land — alongside FDA databases and PubMed.
Hospital procurement & vendor onboarding
Health-system supply chain and IT-security teams require structured public-source verification before adding a vendor to formulary or to the EHR integration list.
Payer & reimbursement review
Commercial payers, CMS and European national health systems check public-source coverage when reviewing coverage and coding decisions for new technologies.
Multi-region regulatory entry
CE marking, MDR, FDA 510(k), PMDA, NMPA — each market reads the public record. German and French Wikipedia editions matter materially for European hospital perception.
Healthcare eligibility patterns
What gets a healthcare company past Wikipedia review
Healthcare notability tends to compound around clinical evidence, regulatory clearances and peer-reviewed publications — Wikipedia editors apply tightened scrutiny to anything that could read as medical-claims promotion.
Strong signal
Regulatory clearances and approvals
FDA 510(k), De Novo, PMA; CE mark under MDR/IVDR; PMDA, TGA, Health Canada approvals — each is independently verifiable through regulator databases and gets covered by trade press substantively.
Strong signal
Peer-reviewed clinical publications
Studies in JAMA, NEJM, Lancet, BMJ or strong specialty journals are gold-standard independent sources. Conference proceedings (RSNA, HIMSS, ASCO, ESMO) at top tier also count.
Strong signal
Health-system or pharma partnerships
Announced deployments at named academic medical centers (Mayo, Cleveland Clinic, Mass General, Charité, AP-HP), or co-development with named pharma — these get covered by health and business press.
Weak signal — common pitfall
Pre-IDE / pre-clinical stage only
Pre-IDE digital health tools and early-stage med-devices typically don't have substantive independent press depth yet. Wait for first regulatory milestone or first published clinical evidence.
Weak signal — common pitfall
Sponsored physician testimonials
Paid speaker engagements, sponsored CME content and clinician testimonials on company sites are not independent. Wikipedia editors actively flag these in healthcare submissions.
Weak signal — common pitfall
Trade-press placements that look paid
Some health trade publications accept "contributed content" that reads as editorial. Wikipedia editors check publication policies and treat undisclosed-sponsorship trade press as not independent.
Pre-FDA / pre-CE healthcare? Wait for the first regulatory milestone — submission, clearance or approval. That single event typically generates the Tier-1 trade press depth required. Until then, the Source Readiness Program is the right path.
Medical-claims considerations
What we will and will not do for healthcare projects
Wikipedia is not the right surface for medical claims, treatment-effect framing or efficacy comparisons. Healthcare drafts stay strictly on facts that are independently verifiable in regulator databases and peer-reviewed literature.
We will
- Reference regulatory clearances with regulator-database citations
- Cite peer-reviewed studies with PubMed / DOI references
- Describe technology and intended use exactly as labeled
- Coordinate timing with regulatory and medical-affairs teams
We will not
- Make efficacy or safety claims beyond cleared indications
- Frame off-label use approvingly or imply non-cleared indications
- Compare directly against named competitor products on outcomes
- Publish during ongoing serious adverse-event investigations
Recommended for healthcare
Recommended
Most healthcare brands need EU + LATAM coverage
Healthcare expansion follows regulatory geography — CE first means German and French Wikipedia matter; LATAM commercialization needs Spanish and Portuguese.
Best fit for global health
Global 7
EN + UK + ES + FR + DE + IT + PT. Covers EU regulatory (DACH, France, Italy), LATAM commercialization (Spanish, Portuguese-Brazil) and Eastern European market entry.
€10,070 net
Choose Global 7
For APAC/MENA
Global 10
Adds Arabic, Japanese and Chinese for healthcare brands with PMDA, NMPA or GCC regulatory pathways. Common for diagnostics, imaging and digital therapeutics scaling into Asia.
€13,974 net
Discuss Global 10
English remains the pricing anchor; bundle savings apply to add-on language editions only. Final language mix is adapted during the audit phase based on your actual regulatory pathway and commercialization plan.
Healthcare-specific questions
Common questions from healthcare and digital-health operators
We're pre-FDA / pre-CE — should we wait?
Yes. The first regulatory milestone (510(k), De Novo, CE under MDR) is typically the event that generates the Tier-1 health-trade press depth Wikipedia needs. Pre-clearance, the source base is usually too thin. Use the Source Readiness Program to map gaps in the meantime.
Can we cite our own clinical trial publications?
Yes — peer-reviewed publications are independent sources even when authored by your team, because the journal's editorial process and peer review provide the independence. Conference posters and abstracts carry less weight; full peer-reviewed papers are the strongest citations available in healthcare.
What about ongoing FDA discussions or pre-submission meetings?
Not citable. Pre-submission interactions with FDA are non-public and shouldn't be referenced in a Wikipedia article. We work only from public regulatory record (cleared / approved / withdrawn). Sometimes this means waiting through a 510(k) cycle before submission makes sense.
How do you handle adverse events or recalls in the article?
If significant adverse events or recalls are part of the public record (FDA MAUDE, EUDAMED), Wikipedia editors will expect them included neutrally — the article is encyclopedic, not promotional. Trying to omit them is a fast path to a deletion nomination. We frame them factually with regulator-database citations.
Digital therapeutics specifically — different rules?
DTx companies face the same notability rules but have a smaller pool of trade press. We weight HIMSS coverage, peer-reviewed clinical evidence, FDA's Digital Health Software Precertification participation and named-payer coverage decisions when assessing source readiness. Pure consumer-app coverage typically isn't substantial enough.
Get started
Find out what's possible for your healthcare company
An audit reviews your regulatory clearances, peer-reviewed evidence base and partnership coverage. We coordinate with your regulatory and medical-affairs teams to ensure the article respects labeled-indication boundaries.